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Summary  2 
Through the initiative of Gavi, The Vaccine Alliance, new vaccines are being 3 
introduced at an unprecedented rate in most of the developing world while 4 
assessments of vaccine impact, effectiveness and safety under real life conditions are 5 
only rarely undertaken, especially in sub-Saharan Africa. 6 
The Kilifi Vaccine Monitoring Study (KiVMS) is a large continuous population based 7 
cohort study in Kenya designed to enable assessments of vaccine safety, direct and 8 
indirect protection, and population immunity via nested sero-prevalence surveys. In 9 
addition, it provides data to support mathematical models of the benefits and cost 10 
effectiveness analyses for vaccines. It is being used to validate methods for assessing 11 
vaccine coverage, to identify sub populations with low immunisation coverage as 12 
targets for interventions, and to assess the non-specific effects of vaccination. 13 
These are all facilitated by the unique integration of a vaccine registry or 14 
immunisation system, a morbidity surveillance system (at the Kilifi County Hospital) 15 
and the Kilifi Health and Demographic Surveillance System (HDSS). Participants are 16 
recruited at birth or in-migration into the study area- Kilifi, a rural Indian Ocean 17 
coastal part of Kenya. Vaccination events are recorded in real-time in the study area, 18 
adult and paediatric hospital admissions undergo detailed clinical and laboratory 19 
evaluation(s), and re-enumeration of all births, deaths, and migration events occurs 3 20 
times a year. 21 
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Requests for data and other enquiries can be submitted to the data governance 2 
committee, KEMRI-Wellcome Trust Research Programme [dgc@kemri-3 
wellcome.org and MOdhiambo@kemri-wellcome.org] 4 
  5 
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Why was the cohort set up?  2 
Childhood vaccination programmes have significantly reduced childhood morbidity 3 
and mortality. (1) Since 2000, there has been an unprecedented expansion of routine 4 
childhood vaccination and increased access to new vaccines in developing countries. 5 
(2, 3) Vaccines protect the individual recipient (direct protection) but they may also 6 
protect the whole population (indirect protection) if they interrupt the chain of 7 
transmission of the target disease. (4, 5) Good quality population and individual level 8 
epidemiological data are needed to estimate direct and indirect effects and inform 9 
vaccination policy at national level. To assure society that a vaccine programme is 10 
safe, it is also necessary to monitor for adverse events following immunisation 11 
(AEFI).  12 
During the introduction and expansion of access to new vaccines in low and middle-13 
income countries (LMICs), relatively little investments are allocated to evaluate the 14 
impact and cost effectiveness of vaccination programmes which are required to 15 
achieve long-term sustainability of new vaccine programmes in LMICs. The capacity 16 
for these kinds of impact assessments has lagged significantly behind the introduction 17 
of new vaccines. As a result, only a very small number of low-income countries have 18 
the platforms required to assess vaccine impact, effectiveness and safety. Some 19 
countries have national or sub-national platforms for monitoring vaccine coverage e.g. 20 
in Health and Demographic Surveillance Systems, periodic multi-indicator cluster 21 
surveys, and Demographic and Health Surveys (DHS). Although these can be linked 22 
to mortality surveillance in HDSS sites to determine the population effects of 23 
vaccines, data quality and interpretation is limited.  24 
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The Kenya Medical Research Institute-Wellcome Trust Research Programme 2 
(KWTRP) in Kilifi set up the Haemophilus influenzae type b (Hib) conjugate vaccine 3 
effectiveness study in 2000. It was further expanded in 2008 with addition of the real 4 
time vaccine-monitoring component, in anticipation of the introduction of 5 
pneumococcal conjugate vaccine (PCV) in Kenya. The objective of the Kilifi Vaccine 6 
Monitoring Study (KiVMS), a long-term continuous cohort study, is to investigate 7 
effectiveness, impact, coverage, safety and indirect vaccine effects by recruiting birth 8 
cohorts as well as cohorts of older children and adults where applicable, within a well-9 
characterised population and area. In addition, KiVMS is used to explore the 10 
determinants of vaccine coverage and acceptability in the population. Built on the 11 
platform of a Health and Demographic Surveillance System (HDSS), KiVMS 12 
integrates morbidity surveillance systems at the County Department of Health 13 
(CDOH), Kilifi and a population-based, computerized information system for 14 
collecting vaccination data. Therefore it has the following essential attributes: 15 
continuously updated demographic data from the population of interest (e.g. births, 16 
deaths and migration); and complete and accurate vaccination records for the 17 
catchment population. Vaccine information systems are rare in tropical Africa.  18 
Here, we describe the study population, and provide an overview of the data sources 19 
and data management processes 20 
Who is in the cohort? 21 
Setting 22 
Kenya is divided administratively into 47 counties. (6, 7) Kilifi County, on the Indian 23 
Ocean Coast, is one of the poorest (6) and is typical of a rural equatorial Africa 24 
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setting. KiVMS is based in Kilifi with the area covered by the Kilifi HDSS (KHDSS) 2 
as shown in figure 1. The KHDSS has a population of 280,000 covering an area of 3 
891 km2. (8) 4 
Inclusion 5 
The primary target of this study is the population of children aged <5 years, resident 6 
in the study area. The KHDSS has a birth cohort of ≈8000 per annum. In addition, all 7 
childhood in-migrants are recruited, along with their families, into the KiVMS during 8 
re-enumeration rounds. From January 2011 to December 31, 2014, there were 33,962 9 
children in the birth cohort database. 10 
Community engagement and governance 11 
KiVMS was conceived at the outset as collaboration between the Ministry of Health 12 
and the KWTRP. A Memorandum of Understanding between both parties guides this 13 
collaboration. Its purpose is to support national and regional policy making by 14 
providing informative local data.  In addition, this resource provides evidence to 15 
support the functions of the newly established Kenya National Immunisation 16 
Technical Advisory Group (KENITAG). 17 
Ethical approval 18 
The KEMRI Scientific and Ethics Review Unit approved this study and the activities 19 
carried out on the KHDSS platform. 20 
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What has been measured? 2 
Basic demographic data 3 
Basic demographic data is obtained from the KHDSS platform. In brief, these include 4 
GIS mapping of homestead location, household name and head, individuals, residency 5 
status, births, deaths and migration. The KHDSS is a longitudinal surveillance of the 6 
population living in a well-defined geographic area around Kilifi County Hospital 7 
(KCH), which has been updated through household visits, monitoring vital events and 8 
migration since the year 2000.(8)  9 
Ascertainment of vaccination 10 
Using an electronic vaccine monitoring system established at all 34 health facilities 11 
delivering vaccines and 53-affiliated outreach sites in the KHDSS (Figure 1); data 12 
clerks record vaccine data (table 1). Vaccine clinics are either government (26) or 13 
privately (8) owned and located within or just outside the KHDSS boundaries. 14 
Children presenting to these are matched to their unique personal record in the 15 
population register. If their details do not exist in the KHDSS database, they are 16 
registered as new once matched to the mother’s homestead and details. If they are not 17 
matched to a household, they are registered with a temporary identification pending 18 
resolution of the associated data query.  Manual registers provide a source of back-up 19 
data for verification like the vaccine cards retained by mothers/care givers, which are 20 
labelled with a unique identity number. Linkage of clinic and central server data is 21 
achieved weekly; data captured at the clinics during daily operations are uploaded to 22 
laptops brought on site by data supervisors and the latest version of the population 23 
register is downloaded to data clerk’s laptops. The population register is also updated 24 
with data of children newly registered at the vaccine clinics and previously unknown 25 
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to the KHDSS. All of the data are delivered to the central data server at the KWTRP. 2 
The synchronisation lag time is usually 1-week. The linkages between the constituent 3 
parts of the KiVMS are outlined in Figure 2. 4 
Morbidity Surveillance 5 
All paediatric and adult admissions undergo detailed clinical and laboratory 6 
evaluation(s) for vaccine preventable diseases surveillance at the KCH - a 172-bed 7 
(and 20-cot) facility at the centre of the KHDSS area that provides primary care and 8 
serves as a first-level referral hospital. (8) It is equipped for basic haematological and 9 
biochemical tests and advanced microbiological culture. It also offers basic radio-10 
diagnostic support. (12) Records of births and maternal deaths are also recorded from 11 
the maternity section in real time. KiVMS is supported by a bespoke database and 12 
platform that integrates electronic health records at KCH with vaccination records and 13 
the KHDSS population register. Individuals at admission or delivery are matched with 14 
the population register, creating a permanent link between the patients’ residence 15 
record and the hospital event. Individuals are matched on five criteria: name, sex, date 16 
of birth, residence and homestead characteristics.  17 
Cross sectional surveys 18 
Surveys of intermediary markers of vaccine impact, such as nasopharyngeal carriage 19 
of pneumococci or serological responses to vaccine preventable diseases, are assessed 20 
through recurrent standardised surveys by age-stratified random sampling of the entire 21 
population. These have been used to determine the interruption of transmission of 22 
pneumococci (9) and the population immunity to Hib vaccine (10). In addition, we 23 
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propose to validate epidemiological measures of vaccine coverage using these 2 
samples. 3 
How often have they been followed up?  4 
Vaccination data is recorded at every vaccine clinic visit. Re-enumeration of births, 5 
deaths, and migration events in the KHDSS occurs 3 times a year. (8) Nasopharyngeal 6 
carriage studies are carried out annually and the serological surveys bi-annually. (9) In 7 
addition, births are recorded continuously as they occur or at first contact in the 8 
community during re-enumeration or at clinics during vaccination visits. Morbidity 9 
surveillance at the KCH is continuous. 10 
What has been found? Key findings and publications 11 
Vaccine impact using before-after studies 12 
The introduction, in 2001, of Hib conjugate vaccine (as Pentavalent vaccine with 13 
diphtheria, tetanus, whole-cell pertussis and hepatitis B antigens) was the precipitant 14 
for the development of the KiVMS. Using population linked morbidity surveillance; 15 
we showed an 88% effectiveness of the vaccination programme against invasive Hib 16 
disease incidence among children aged less than 5 years within 3 years of introducing 17 
the vaccine. (11) Fifteen years on, and without a booster dose, vaccine effectiveness is 18 
93% and serosurveys confirm enduring population immunity. (10) 19 
KiVMS currently supports the Pneumococcal Conjugate Vaccine Impact Study 20 
(PCVIS), a before-after study of the impact of the 10-valent pneumococcal conjugate 21 
vaccine (PCV-10) introduced in January 2011. Linkages between the vaccine registry 22 
and morbidity surveillance databases permit an individual-based cohort analysis of the 23 
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entire population by connecting rates of IPD to vaccine status. Dividing the numbers 2 
of IPD cases by the person-years of observation in different exposure strata 3 
(unvaccinated, partially and fully vaccinated) provides estimates of the total and 4 
indirect effects of PCV-10. The impact on the incidence of clinical and radiologically 5 
confirmed pneumonia and invasive pneumococcal disease will be reported in 2016. 6 
KiVMS was recently adapted to estimate the impact of the newly introduced rotavirus 7 
vaccine. Between 2002-2004, incidence of hospitalisations with Group A rotavirus 8 
gastroenteritis was 1,431 (95% Confidence Intervals [CI] 1,275–1,600) per 100,000 9 
person years of observation (pyo) in infants. (12) On-going surveillance shows these 10 
rates have declined appreciably over time pre vaccine introduction in July 2014. It is 11 
important to adjust for secular trends like these in assessments of vaccine impact 12 
especially if this change is thought to be due to changes in associated risk factors. 13 
Rotavirus vaccination impact data will be available in 2017. 14 
Epidemiological studies of transmission and seroprevalence  15 
Following the introduction of PCV-10 with a catch-up campaign in all children aged 16 
<5 years in the KHDSS, annual studies of nasopharyngeal carriage demonstrated a 17 
reduction of 64% (95% CI 49-74%) in the prevalence of vaccine serotype 18 
pneumococci among children aged <5 years. There was also a 66% (95% CI 38-82%) 19 
reduction in carriage prevalence among unvaccinated older children and adults, 20 
illustrating a profound and rapid indirect protection and predicting a decline in IPD 21 
across the whole population. (9)  22 
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Assessments of vaccine coverage, timeliness and equity 2 
KiVMS provides a platform to validate administrative and survey-based methods for 3 
assessing vaccine coverage. Similar to others, (13) we found that compared to survey 4 
data, administrative estimates exaggerate vaccine coverage.(14) Within KHDSS, we 5 
have observed that seasonality and family size are strong factors that determine 6 
coverage. (14, 15)  KiVMS allows for review of patterns of coverage over time to 7 
monitor programme performance by birth cohort and locations (Figures 3A-B); it 8 
gives insights into equity of access by its sensitivity for identification of sub-9 
populations with low vaccination coverage (Figure 3C); and can also be used to 10 
investigate vaccine failures and target interventions. Predictors of vaccine inequity 11 
and hesitancy in at-risk groups such as recent migrants, young mothers and in 12 
geographic pockets of poor coverage can also be investigated.  13 
Complex before and after studies 14 
Before-after studies are susceptible to similar biases as case-control studies. In routine 15 
practice, the population of children who are not immunised may differ from the 16 
majority with respect to background incidence or extent to which their disease 17 
outcome can be fully ascertained. An accurate estimate of effectiveness for individual 18 
protection (direct effect) can only be obtained by adjusting for confounding by 19 
‘healthy’ vaccinees (16). It is important to identify these ascertainment biases and 20 
control for them to the extent possible, for example by estimating the protection from 21 
disease by receipt of an unrelated vaccine. The schematic shown in Figure 4 22 
highlights the various cohort and incidence rate comparisons required to estimate the 23 
overall vaccine impact as well as the direct and indirect protection of a vaccine.  24 
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A further complexity arises from secular changes in disease risk factors. As vaccine 2 
‘exposure’ is always associated with time in a before-after study, any risk factor that 3 
also varies with time may be a confounder. In tropical Africa, the risk factors for 4 
vaccine preventable diseases are complex and may include malaria, malnutrition and 5 
HIV infection. Analyses of incidence ratios attributable to vaccination in an 6 
interrupted time series analyses for example (17), can adjust for secular trends in 7 
major confounders but only if these data are available. By virtue of its setting within a 8 
community and hospital-based research station of over 25 years duration, the KiVMS 9 
has access to data on many of these variables. (18)  10 
Vaccine Safety Monitoring 11 
KiVMS follows a relatively small annual birth cohort compared to the national 12 
immunisation programme but it has the capacity to accurately define temporal 13 
associations between recent vaccination and deaths or serious life-threatening events 14 
presenting to hospital. When the WHO considered the introduction of PCV10 as a 15 
two-dose vial without a preservative, they were concerned about the theoretical risk of 16 
bacterial contamination of an opened vial leading to AEFI after the second dose in the 17 
vial. We studied the problem for the first two years of introduction. The absence of 18 
any measurable safety signal in vaccination site abscesses, sepsis or death after 19 
immunisation helped in the approval of PCV10 introduction into other countries using 20 
the 2-dose vial. (19)  21 
Because the mortality burden attributable to many vaccine preventable diseases is 22 
high in sSA, the issue of vaccine safety has not been the primary focus of society. 23 
However, experience from developed countries suggests that vaccines may be valued 24 
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less highly once the target disease has been brought under control and assurances of 2 
safety are essential for the sustainability of the programme.  3 
In 2014, Kenya scaled up its maternal tetanus vaccination programme because earlier 4 
efforts and success had brought the country within range of the global maternal and 5 
neonatal tetanus elimination threshold i.e. incidence < than 1 case per 1,000 live births 6 
(20). Unfortunately, a group of religious leaders accused the government of planning 7 
to sterilise women by giving Beta-Human Chorionic Gonadotropin (HCG)-containing 8 
tetanus vaccines and campaigned against this initiative. (21) To support their position, 9 
they argued the expanded programme was not justified because there were no more 10 
cases of neonatal tetanus in the country. However, data from Kilifi clearly showed the 11 
impact of the immunisation programme and the need to build on the progress 12 
achieved already. (22)  13 
What are the main strengths and weaknesses? 14 
The evaluation of population impact and safety in the diverse epidemiological settings 15 
where vaccines are introduced receives less attention compared to Phase III Trials to 16 
demonstrate individual vaccine efficacy. Although KiVMS has evolved to meet a 17 
specific need in Kenya, its principal strength is its unique integration of a vaccine 18 
registry and a morbidity surveillance system on top of the largest HDSS in Africa. As 19 
a cohort study and integrated surveillance platform, it facilitates population level 20 
vaccine impact assessments. The benefits of such a set-up have recently been 21 
recognised by the INDEPTH network in its recently proposed model: the 22 
Comprehensive Health and Epidemiological Surveillance System (CHESS). (23) It is 23 
a very efficient study template for gathering data on vaccine effectiveness and safety 24 
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that can be copied or deployed across heterogeneous locations in the developing 2 
world.  It has provided evidence of direct and indirect vaccine effectiveness (9, 11), 3 
vaccine safety (19), provided insights into vaccination coverage (14, 15) and 4 
facilitated cost effectiveness analyses using models for pneumococcal,(24) rotavirus 5 
(25) and Hib vaccines (26), that have directly influenced national and regional policy. 6 
Vaccine monitoring is conducted in clinics entirely by CDOH staff. The KWTRP 7 
provides the design, training, data collation, cleaning and analysis. This integration 8 
with the health ministry personnel is another strength of KIVMS that has shaped 9 
significantly by more than a decade of collaboration. This has proven essential both 10 
for the smooth running of the programme and for the effective use of results.  11 
The KEMRI SERU approved the creation of KiVMS as part of the KWTRP. 12 
Importantly, all community-based research at the KWTRP is part of an integrated 13 
system of community engagement using a wide range of channels including 14 
community representative groups and open public meetings to ensure that the research 15 
conducted under KiVMS is locally relevant.  16 
As expected of a resource poor setting, there are challenges of logistics and 17 
infrastructure. The limited coverage and instability of power supplies, along with 18 
inadequate roads and mobile phone networks present tremendous challenges. As the 19 
project did not have capacity for electronic data capture during outreach services 20 
(where health care workers travel intermittently to numerous alternative delivery 21 
points e.g. schools), back-up paper systems were deployed. Supplementary 22 
immunisation activities (e.g. for measles and polio) are also conducted in KHDSS 23 
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communities from time-to-time. However, the present infrastructure of KiVMS only 2 
allows for the recording of routinely delivered vaccinations.  3 
In KiVMS, it is critical to identify individuals accurately from the population register 4 
and link them to events such as vaccination or hospital admission. Identification is 5 
generally easier at vaccine clinics than hospitals because mothers and data clerks 6 
know the local area in detail and geographical residence is a key identity criterion. 7 
However vaccine clinics are very busy environments and personal ID matching is still 8 
slow, and occasionally inaccurate. An incident record is opened when ID mismatches 9 
occurs which is resolved by data supervisors and managers of the vaccine registry and 10 
KHDSS at the KWTRP.  Fingerprinting technology solutions were considered but 11 
would not work for our primary target population-young infants- as their fingerprint 12 
patterns are not reliably distinguished at this age. 13 
Although KHDSS detects in and out migrations in its study area, the data capture in 14 
local clinics cannot record vaccinations received by migrants if they had received all 15 
of their vaccines prior to moving into the area and do not visit the vaccine clinics, or 16 
experience hospitalisation at KCH. In addition, migration itself may be a risk factor 17 
for poor uptake. (27, 28) Consequently, data for migrants is less complete and there is 18 
a risk of misclassification. To capture these data as far as it is practically possible, we 19 
instituted vaccine-card surveillance for KHDSS in-migrants aged <5 years, which are 20 
effectively a small population sample, during re-enumeration rounds. This will 21 
improve completeness of data for this small but often at risk group. In table 2, we 22 
show the merits of an electronic vaccine registry compared to use of HDSS 23 
enumeration rounds for routine collection of all vaccine data. 24 
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KHDSS, the largest surveillance of its kind in tropical Africa, is suitable for the study 2 
of vaccine impacts against common diseases (e.g. invasive Hib and pneumococcal 3 
disease) but cannot provide the richness of detail e.g. strain-specific or age-specific 4 
vaccine efficacy afforded by national surveillance systems.  This limitation is most 5 
apparent in the study of vaccine safety as the levels of severe AEFI for licensed 6 
vaccines are infrequent in epidemiological terms and cannot easily be associated with 7 
vaccine in a population of this size. One solution to this is to link several HDSS 8 
platforms together, within country, as we have done in Kenya to examine PCV10 9 
safety. (19) 10 
Can I get hold of the data? Where can I find out more? 11 
Investigators with interest in datasets or collaborations can contact Millicent 12 
Odhiambo (modhiambo@kemri-wellcome.org) and the KWTRP data governance 13 
committee (dgc@kemri-wellcome.org) with a statement of request and formal 14 
application for data transfer. In addition, they can contact the principal investigator, 15 
Professor Anthony Scott (ascott@kemri-wellcome.org) and/or co-investigator, Dr. 16 
Ifedayo Adetifa (IAdetifa@kemri-wellcome.org). There is more information on the 17 
KWTRP website, www.kemri-wellcome.org. 18 
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 2 
Key Messages 
• The Kilifi Vaccine Monitoring Study (KiVMS) is a long-term continuous cohort 
study set up to investigate the effectiveness, impact, coverage, safety and indirect 
vaccine effects by recruiting birth cohorts and where applicable, cohorts of older 
and adults.  
• It is based in the area covered by the Kilifi Health and Demographic Surveillance 
System, Kilifi, Kenya and currently has records of 33, 962 children in the birth 
cohort database. 
• A major strength of KiVMS is its unique integration of a vaccine registry, a 
morbidity surveillance system and the largest health and demographic surveillance 
system (HDSS) in Africa. 
• Requests for data and/or collaboration should be sent to dgc@kemri-wellcome.org 
and MOdhiambo@kemri-wellcome.org  
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